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revealed a relatively high level of AIAT against AUAT to Tg – 0.343
± 0.027 CU (Group II). In patients with thyroid cancer without
metastases, the level of AIAT against AUAT to Tg (0.185 ± 0.083 CU)
was lower than that of cancer patients with metastases.
Metastatic cancer cannot be differentiated from cancer without
metastases in 23% of studied cases.
The level of AUAT to Tg in patients with thyroid cancer in the
group I was 0.997 ± 0.084 CU and in the group II was 1.087 ± 0.174
CU. The level of AUAT to TG in cancer patients without metastasis
was 0.794 ± 0.038 CU. It was found that when the level of AIAT
against AUAT to Tg does not allow to distinguish metastatic
thyroid cancer from cancer without metastases, it is possible to
differentiate status data of thyroid cancer by using the level of
autoantibodies to Tg.
Moreover, the high level of AIATagainst AUAT to Tg in patients
with cancer without detectable metastases may be a marker of
poor prognosis. So in one of the studied patients diagnosed with
papillary cancer without metastasis, the level of AIAT against
AUAT to Tg was equal to 0.37 CU, thus indicating the presence
of metastases. Indeed, metastases were found in this patient 4
months later.
Thus, the level of anti-idiotypic antibodies against autoanti-
bodies to thyroglobulin may be used as a marker for metastases
in the differential diagnosis of thyroid cancer.
http://dx.doi.org/10.1016/j.ejcsup.2015.08.041
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Purpose: DNA minor groove is the main target of small mole-
cules, which noncovalently and to a certain extent site-
specifically bind to appropriate nucleotide sequences. Study of
these substances can give rise to understanding the mechanistic
relationship between sites of interaction and activity of
appropriate enzymes with ‘‘houskeeping” function including
helicases, topoisomerases, methyltransferases, demethylases
and DNA/RNA-polymerases.
Results: We revealed for the first time that AT-specific minor
groove binding ligands (MGBLs), in particular bisbenzimidazoles
(Hoechst33258 and its derivatives), widely used in molecular
and cell biology for DNA-staining, induce loss of heterozygosity
at high frequency while point mutations and chromosome dele-
tions at insignificant levels. Moreover, we demonstrated that the
agents realized their genotoxic blastomogenic effects via homol-
ogous recombination mechanism exclusively. Lately the same
mechanism of genotoxicity has been shown for MGBL carbazole
derivative Curaxin, which is toxic for a broad range of tumor cell
lines in vitro and inhibit tumor growth in different mouse models
of cancer in vivo. Moreover, powerful antitumor activity has been
demonstrated for Trabectedin, which binds to the DNA’s minor
groove and alkylate guanine residues. All this provided a frame-
work for wide-ranging investigation of cell response to MGBLs
exposure, molecular mechanisms of their recombinogenic as also
their anticancer activity. A special interest is paid to epigenetic
mechanisms of MGBs action.
Our study aimed to examine the epigenetic effects of recom-
binogenic (Hoechst33342, Hoechst33258) and non-recombinogenic
(DAPI, Diminazene, Pentamidine and Netropsin) MGBLs.
After we unmasked MGBLs’ recombinogenic activity, we
hypothesized that their molecular mechanism of indirect DNA
damage involves poly(ADP-ribose)polymerase-1 (PARP-1) activa-
tion. Surprisingly, we found that all AT-specific MGBLs preventing
PARP-1 interaction with DNA inhibit its activation, and hence, the
DNA-dependent pathway of PARP-1 activation function. These
inhibitors effectively block PARP-1 activity in vivo, as it was
demonstrated in a Drosophila experimental system and in
human breast cancer-derived BT474 cell line.
Further epigenetic effects of these indirect genotoxic carcino-
gens were analyzed using HeLa cell population with epigeneti-
cally suppressed GFP-reporter gene as a model. All compounds
had strong GFP- reactivation effect. The obtained results confirm
scarce data of previous publications on the ability of DNA minor
groove ligands to influence gene transcription process. Statisti-
cally significant results of changes of DNAmethylation level were
detected under 5-azaC and Hoechst 33258 treatment, but it was
absent after Hoechst 33342 treatment. For the rest compounds
significant loss of promoter region methylation was not observed.
The common epigenetic marks of transcription include histone
H3 trimethylation in lysine 4 (H3K4me3) and histone H3 and H4
acetylation (acH3/acH4) on promoter regions of genes. We
showed that TSA, Hoechst 33342 and DAPI treatment of HeLa-TI
cells lead to increased level of histone H3 trimethylation of
lysines 4 (H3K4me3), but for all that the level of histone H4
acetylation remains without significant changes. On the contrary,
histone H3 acetylation level was stably increased at all samples.
The modifications are typical for silent genes and decrease of
their amount suggests the transcriptional reactivation. Loss of
H4K20me3 mark in comparison with untreated control was
demonstrated for MGBLs.
Conclusion: Taking together, findings of the study will lay the
fundamental groundwork for the development of novel anti-
cancer strategies and new chemotherapy effects of small mole-
cules. The mechanism of PARP-1 inhibition by MGBLs and its
epigenetic influence on silent genes, via DNA methylation and
histone modifications make reasonable further study of these
compounds in three prospective directions: (1) as self-acting
cytotoxic agents; (2) as a component of combined chemotherapy
targeting DNA repair by PARP-1, thereby facilitating DNA damage
caused by other anticancer drugs; (3) as an agents reactivating
epigenetically repressed genes which silencing occurs during
the earliest stages of neoplasia and accumulates with progression
toward malignancy.
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